DEFA14A: Masimo Urges Stockholders to Reject Politan's Bid for Control, Citing Risks to Innovation and Value Creation

Masimo is actively campaigning against Politan Capital's attempt to gain control of the company, arguing that Politan's actions threaten stockholder value and the company's innovation-driven growth strategy.

Summary

• Masimo has filed an investor presentation urging stockholders to vote for its director nominees, Joe Kiani and Christopher Chavez, at the upcoming Annual Meeting on July 25, 2024.
• The presentation highlights Masimo's history of innovation, strategic initiatives for growth and margin expansion, and the risks associated with Politan Capital's attempt to gain control without paying a premium.
• Masimo argues that Politan's nominees are inferior and lack the experience to lead the company, and that Politan's actions are a threat to stockholder value.
• The company is pursuing a separation of its consumer business, which is expected to double operating margin to approximately 30% by 2029 and drive non-GAAP EPS to around $8 by 2029.
• Masimo claims that Politan's directors have offered no actionable strategic or operational suggestions, failed to deliver any value-creative solutions for the Consumer Business, and obstructed key initiatives.
• The company has made multiple settlement offers to Politan, all of which were rejected as Politan demanded control without paying a premium.
• Masimo's presentation emphasizes its innovation engine, which has driven a premium valuation and strong foundation for future growth, with an 11% revenue CAGR since IPO and a 5% median annual EPS beat over the last 10 years.
• The company's strategic initiatives include expanding its footprint with existing customers, winning new customers, and executing a multi-pronged margin expansion strategy.
• Masimo is positioned to generate significant value for stockholders by leveraging industry-leading technology in pulse oximetry, advanced parameters, and hospital automation and telemonitoring.
• The company's R&D spend is in line with industry peers, and its innovation engine continues to deliver a leading healthcare portfolio meriting a premium valuation.

Sentiment

Score: 6

Explanation: The document is primarily defensive, aimed at countering Politan's influence. While it highlights positive aspects of Masimo's performance and future plans, the overall tone is cautious and concerned about the potential negative impact of Politan's involvement.

Positives

• Masimo has a robust track record of innovation, led by CEO Joe Kiani, that supports its valuation premium.
• The company has strategic initiatives for sustained growth and margin expansion, with a goal of ~$8 Non-GAAP EPS by 2029.
• Masimo is pursuing a separation of the Consumer Business to maximize shareholder value.
• The company's healthcare business is on track for growth, with a solid foundation built on expanding its footprint with existing customers and winning new customers.
• Masimo is executing a multi-pronged margin expansion strategy, with a 5-year goal of ~30% operating margin for the professional healthcare business.
• The company has a growing driver installed base, which has enabled connected care with a system-wide platform driving superior clinical outcomes.
• Masimo has sticky, long-term customer contracts with hospitals, driving a recurring revenue model.
• The company has multi-year partnerships with OEM partners such as Philips and GE Healthcare.
• Masimo has a global health market expansion strategy to address care gaps in developing markets.
• The company's R&D spend is in line with industry peers.

Negatives

• Politan is attempting to gain control of Masimo without paying a premium or articulating a clear plan.
• Politan's directors have offered no actionable strategic or operational suggestions and have failed to deliver any value-creative solutions for the Consumer Business.
• The Politan directors have obstructed or schemed to delay key initiatives desired by other stockholders.
• Politan's actions have impacted sentiment following a positive Masimo announcement, potentially depressing the stock price.
• The Politan directors have been consistently obstructive, threatening, and counterproductive to the interests of the company and its stockholders.
• Politan seeks to eliminate substantial experience and relevant expertise from the Masimo boardroom by replacing highly qualified director nominees with inferior candidates.
• Politan's nominees lack prior public company CEO experience or the ability to step into the CEO role.
• Politan's poor track record at Centene and Azenta raises concerns about their ability to add value at Masimo.
• The company faces uncertainties regarding the Potential Separation of the consumer business.
• The company faces uncertainties regarding future actions that may be taken by Politan in furtherance of its nomination of director candidates for election at the 2024 Annual Meeting.

Risks

• Politan's attempt to gain control could disrupt Masimo's organizational culture, innovation premium, and future growth.
• The potential separation of the consumer business involves uncertainties and risks, including the ability to effect or complete the separation on the terms described.
• The company faces potential cost and management distraction attendant to Politan's nomination of director nominees at the 2024 Annual Meeting.
• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• The company's success depends on its ability to continue innovating and launching successful products.
• The company faces competition from other medical technology companies.
• The company's business is subject to regulatory risks.
• The company's business is subject to economic risks.
• The company's business is subject to litigation risks.
• The company's business is subject to cybersecurity risks.

Future Outlook

Masimo anticipates significant growth in its professional healthcare business, driven by expanding its footprint with existing customers, winning new contracts, and increasing adoption of its technology platforms, with a long-term goal of ~$8 earnings per share for the professional healthcare business.

Management Comments

• Masimo's management believes that Politan's commitment to willful ignorance of how the innovation engine drives value for stockholders puts the company's future at risk.
• Masimo's management believes that if Politan seizes control, the future of the company and the value of your investment are at risk.
• Masimo's non-Politan independent directors believe Koffey poses a serious risk to the value of the company given his profound failure to appreciate that Masimo's value is derived from its track record as an innovation-based company.

Industry Context

The document positions Masimo as a leading medical technology company with a history of innovation and a premium valuation compared to its peers, while highlighting the risks of ceding control to an activist investor who may not understand the company's long-term strategy and value drivers.

Comparison to Industry Standards

• Masimo's R&D spend is in line with industry peers.
• The market has valued Masimo at nearly double the peer multiple (19A 23A NTM P/E).
• Masimo's current NTM P/E premium is 16.7x over select MedTech peers.
• Masimo's gross margin is 62.5%, which is in line with industry peers.
• Masimo's SG&A expenses are ~29%, which is lower than industry peers.
• Masimo's R&D expenses are ~9% 10%, which is in line with industry peers.

Corporate Governance

Legal Proceedings

• The document references ongoing litigation with Apple and litigation related expenses and settlements.

Stakeholder Impact

• The outcome of the proxy contest will significantly impact shareholders, as it will determine the direction and leadership of the company.
• Employees may be affected by potential changes in strategy or leadership resulting from the proxy contest.
• Customers may be impacted by any changes in product development or service offerings.
• Suppliers and creditors may be affected by any changes in the company's financial performance or strategic direction.

Next Steps

• Stockholders are encouraged to vote FOR Joe Kiani and Christopher Chavez on the GOLD Proxy Card.
• The company will continue to evaluate the proposed separation of its consumer business.
• The company will continue to execute its strategic initiatives for growth and margin expansion.

Key Dates

Keywords

Masimo, Politan, proxy contest, director nominees, innovation, consumer business separation, stockholder value, healthcare, medical technology, governance